Jinny Jeffery1, Zoe J Vincent1, Ruth M Ayling1, Stephen J Lewis2. 1. Derriford Combined Laboratory, Derriford Hospital, Plymouth PL6 8DH, UK. 2. Department of Gastroenterology, Derriford Hospital, Plymouth PL6 8DH, UK. Electronic address: sjl@doctors.org.uk.
Abstract
BACKGROUND: Metronidazole is an oral antibiotic which is widely used in the treatment of patients with Clostridium difficile associated disease. METHODS: This article describes the validation of a LC-MS/MS assay for the measurement of metronidazole in human faecal samples. RESULTS: Matrix matched and aqueous standards showed no significant difference in performance for the routine calibration of the assay. D4 deuterated metronidazole internal standard eluted with a different retention time to the undeuterated metronidazole on chromatography, hence zidovudine was used as an internal standard. Ion suppression was noted for both metronidazole and zidovudine due to unidentified compounds present in the faecal matrix and this was improved by extracting a smaller quantity of faeces and diluting the extract prior to analysis. Measurement uncertainty was 13% at 28,400ng/ml, 7.2% at 3300ng/ml, 3.9% at 320ng/ml, 13.6% at 109ng/ml and 30.9% at 20ng/ml. The assay was shown to be linear on dilution and the sensitivity of the assay was superior to HPLC assays using UV detection. The limit of detection was 5ng/ml, the limit of quantitation was 66ng/ml and the upper limit of the working range was 30,000ng/ml. Patient samples were stable at -20°C for 12months and extracted faecal samples were stable on storage for 1week at 4°C. There were no specific requirements for patient preparation or time of sample collection relative to taking metronidazole. CONCLUSIONS: Metronidazole can be quantified in faecal samples using LC-MS/MS which opens up opportunities for further research in this area.
BACKGROUND:Metronidazole is an oral antibiotic which is widely used in the treatment of patients with Clostridium difficile associated disease. METHODS: This article describes the validation of a LC-MS/MS assay for the measurement of metronidazole in human faecal samples. RESULTS: Matrix matched and aqueous standards showed no significant difference in performance for the routine calibration of the assay. D4 deuterated metronidazole internal standard eluted with a different retention time to the undeuterated metronidazole on chromatography, hence zidovudine was used as an internal standard. Ion suppression was noted for both metronidazole and zidovudine due to unidentified compounds present in the faecal matrix and this was improved by extracting a smaller quantity of faeces and diluting the extract prior to analysis. Measurement uncertainty was 13% at 28,400ng/ml, 7.2% at 3300ng/ml, 3.9% at 320ng/ml, 13.6% at 109ng/ml and 30.9% at 20ng/ml. The assay was shown to be linear on dilution and the sensitivity of the assay was superior to HPLC assays using UV detection. The limit of detection was 5ng/ml, the limit of quantitation was 66ng/ml and the upper limit of the working range was 30,000ng/ml. Patient samples were stable at -20°C for 12months and extracted faecal samples were stable on storage for 1week at 4°C. There were no specific requirements for patient preparation or time of sample collection relative to taking metronidazole. CONCLUSIONS:Metronidazole can be quantified in faecal samples using LC-MS/MS which opens up opportunities for further research in this area.
Authors: Ludmila Alexandrova; Farhana Haque; Patricia Rodriguez; Ashton C Marrazzo; Jessica A Grembi; Vasavi Ramachandran; Andrew J Hryckowian; Christopher M Adams; Md Shah A Siddique; Ashraful I Khan; Firdausi Qadri; Jason R Andrews; Mahmudur Rahman; Alfred M Spormann; Gary K Schoolnik; Allis Chien; Eric J Nelson Journal: J Infect Dis Date: 2019-10-08 Impact factor: 5.226